Epilepsy

Epilepsy · Neurology · 6 drugs · 7 indications

Seizure disorder.
Competitive Landscape (6 drugs)
DrugCompanyMechanismModalityRouteStage
PadsevonilUCBSV2A/GABAA modulatorSmall moleculePOPHASE3
STACCATO alprazolamUCBGABA-A receptor modulator (benzodiazepine)Small molecule (inhaled)InhaledPHASE3
BriviactUCBSV2A ligandSmall moleculePOAPPROVED
KeppraUCBSV2A ligandSmall moleculeOral/IVAPPROVED
VimpatUCBSodium channel blocker (VGSC)Small moleculePOAPPROVED
NayzilamUCBGABA-A receptor modulator (benzodiazepine)Small moleculeNasalAPPROVED
Indications (7)
Epilepsy, focal onset seizures
Focal onset seizures
Briviact APPROVEDKeppra APPROVEDVimpat APPROVED
Drug-resistant focal epilepsy
Padsevonil PHASE3
Acute repetitive seizures
Nayzilam APPROVED
Primary generalized tonic-clonic seizures
Vimpat APPROVED
Stereotypical prolonged seizures
STACCATO alprazolam PHASE3
Refractory focal epilepsy
Padsevonil PHASE3
Upcoming Catalysts
STACCATO Alprazolam - Seizures - Ph3 - Headline ResultsCLINICAL
UCBH1 2026
Padsevonil - Drug-Resistant Epilepsy - Ph3 - UpdatesCLINICAL
UCB2026
Data from Supabase · Updated 2026-03-24